AR026179A1 - Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen - Google Patents

Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen

Info

Publication number
AR026179A1
AR026179A1 ARP000105513A ARP000105513A AR026179A1 AR 026179 A1 AR026179 A1 AR 026179A1 AR P000105513 A ARP000105513 A AR P000105513A AR P000105513 A ARP000105513 A AR P000105513A AR 026179 A1 AR026179 A1 AR 026179A1
Authority
AR
Argentina
Prior art keywords
medicines
well
heterociclically
benzoilguanidinas
employment
Prior art date
Application number
ARP000105513A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR026179A1 publication Critical patent/AR026179A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen benzoilguanidinas heterocíclicamente sustituidas de la formula 1 en las cuales los sustituyentes R(1) a R(4) tienen los significados en lasreivindicaciones. Estos compeustos 1 sona decuados como medicamentos antiarrítmicos con componente s cardioprotectores para la profilaxis de infarto y para eltratamiento de infarto así como para el tratamiento de la angina de pecho. Los mismos inhiben también preventivamente los procesos patofisiologicos en el casode la génesis de danos inducidos isquémicamente, especialmente en el caso del desencadenamiento de arritmias cardíacas inducidas isquémicamente.
ARP000105513A 1999-10-22 2000-10-19 Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen AR026179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19950898A DE19950898A1 (de) 1999-10-22 1999-10-22 Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR026179A1 true AR026179A1 (es) 2003-01-29

Family

ID=7926515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105513A AR026179A1 (es) 1999-10-22 2000-10-19 Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen

Country Status (10)

Country Link
US (3) US20010049446A1 (es)
EP (1) EP1226124A1 (es)
JP (1) JP2003512457A (es)
CN (1) CN1373757A (es)
AR (1) AR026179A1 (es)
AU (1) AU7663000A (es)
CZ (1) CZ20021218A3 (es)
DE (1) DE19950898A1 (es)
EE (1) EE200200142A (es)
WO (1) WO2001030761A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
CA2470365C (en) * 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1602648B1 (en) * 2003-03-13 2013-04-17 Idemitsu Kosan Co., Ltd. Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same
US20050124666A1 (en) 2003-11-13 2005-06-09 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665739A (en) 1992-12-15 1997-09-09 Hoechst Aktiengesellschaft Substituted benzoylguanidines, process and their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
TW250479B (es) * 1992-12-15 1995-07-01 Hoechst Ag
DE4328869A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4430861A1 (de) 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine

Also Published As

Publication number Publication date
DE19950898A1 (de) 2001-04-26
EE200200142A (et) 2003-04-15
US6617344B2 (en) 2003-09-09
CN1373757A (zh) 2002-10-09
US20010049446A1 (en) 2001-12-06
CZ20021218A3 (cs) 2002-06-12
WO2001030761A1 (de) 2001-05-03
US20030139607A1 (en) 2003-07-24
AU7663000A (en) 2001-05-08
EP1226124A1 (de) 2002-07-31
JP2003512457A (ja) 2003-04-02
US20020099222A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
NO20050078L (no) Fluorerte sykloalkyl-derivatiserte benzoylguanidiner og deres anvendelse som medikament
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CR6592A (es) Compuestos para el tratamiento de la isquemia
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
ECSP003591A (es) Antibacterianos
NO20032488D0 (no) Orto-substituerte nitrogen-inneholdende bisarylforbindelser anvendt som kaliumkanalinhibitorer
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
AR004253A1 (es) Sulfonimidoamidas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico asi como medicamento quelas contiene.
AR043175A1 (es) Modificacion cristalina del anhidrato de boscalida
ES2154002T3 (es) 2-naftoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
AR026179A1 (es) Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen
NO20045447L (no) Pentafluorsulfanyl-benzoylguanidiner, fremgangsmate for deres fremstilling, deres anvendelse som legemiddel eller diagnostisk middel samt medikamenter inneholdende disse
AR008761A1 (es) Benzoil-guanidinas sustituidas en orto, procedimiento para su preparacion, su utilizacion como medicamento, asi como medicamento que las contiene
NO20062635L (no) Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse
GT200600293A (es) Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3,5-disustituidas.
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
ES2155223T3 (es) 1-naftoilguanidinas sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
AR004318A1 (es) Benzoil-guanidinas sustituidas con sulfonilamino, procedimiento para su preparacion, su empleo como medicamento o para diagnostico, asi como elmedicamento que las contiene.
AR006051A1 (es) Benzoilguanidinas sustituidas en posicion orto, su utilizacion para la preparacion de un medicamento para la profilaxis y tratamiento de infarto,angina de pecho, estados isquemicos y de proliferacion celular.
AR007497A1 (es) Benzoilguanidinas bis-orto-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamentoque las contiene
AR005596A1 (es) Diguanididas de acidos diarildicarboxilicos sustituidos, un procedimiento para su preparacion, su utilizacion como medicamento o agente diagnostico,asi commo un medicamento que las contiene.
ES2062570T3 (es) L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias.
UY28358A1 (es) Derivados de 3-(guanidinocarbonil)heterociclos, procedimiento de preparación y compuestos intermedios de este procedimiento, su uso como medicamentos, y composiciones farmaceuticas que los incluyen.
AR006052A1 (es) Benzoilguanidinas sustituidas en posicion orto, un procedimiento para su preparacion, su utilizacion como medicamento, asi como medicamento que lascontiene
BRPI0515148A (pt) benzoilguanidinas pentafluorsulfanilfenila-substituìdas, método para produção das mesmas, seu uso como medicamento ou agente de diagnóstico, e um medicamento contendo estes compostos